ArticleOncology reports2021
Identification of the tumor‑suppressive role of circular RNA‑FOXO3 in colorectal cancer via regulation of miR‑543/LATS1 axis.
Article in Oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Research progress of circular RNA FOXO3 in diseases (review).Global medical genetics · 2025Review
- circPOLA2 promotes proliferation, invasion, migration, and epithelial-mesenchymal transition in breast cancer via the miR-1224-5p/HMGA2 axis.Clinics (Sao Paulo, Brazil) · 2025Article
- CircRNAs in colorectal cancer: potential roles, clinical applications, and natural product-based regulation.Frontiers in oncology · 2025Review
- Plasma Circular RNAs as Biomarkers for Breast Cancer.Biomedicines · 2024Review
- Circ_0000370 Plays an Oncogenic Role in Colorectal Cancer by Regulating the miR-502-5p/SIRT1 Axis.Biochemical genetics · 2024Article
- A therapeutical insight into the correlation between circRNAs and signaling pathways involved in cancer pathogenesis.Medical oncology (Northwood, London, England) · 2024Review
- The regulatory roles of circular RNAsFrontiers in neurology · 2022Review
- Circular RNAs modulate Hippo-YAP signaling: functional mechanisms in cancer.Theranostics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a common malignancy with significant prevalence and mortality rates. Circular RNA FOXO3 (circ‑FOXO3; hsa_circ_0006404) has been reported to be involved in cancer regulation; however, its role in CRC is yet to be fully elucidated. Therefore, the aim of the present study was to investigate the effect of circ‑FOXO3 on CRC progression and identify its underlying mechanism. In the present study, the expression of circ‑FOXO3 was investigated in CRC tissues and cells via reverse transcription‑quantitative PCR. A Cell Counting Kit‑8 and colony formation assays were used to assess cell proliferation. The cell migratory and invasive abilities were detected using the Transwell migration and invasion assays. The luciferase assay and RNA pull‑down assay were conducted to verify the relationship of circ‑FOXO3, microRNA (miR)‑543 and Large tumor suppressor kinase 1 (LATS1). The results demonstrated that circ‑FOXO3 expression was downregulated in CRC tissues and cells, and was associated with poor overall survival of patients with CRC. Moreover, circ‑FOXO3 was associated with tumor size, distant metastasis, differentiation, lymph node metastasis and TMN stages of patients with CRC. circ‑FOXO3 overexpression suppressed CRC cell proliferation, migration and invasion. Luciferase assay and RNA pull‑down assay results indicated that circ‑FOXO3 functioned as a sponge for miR‑543. In addition, circ‑FOXO3 increased the expression of LATS1 via sponging miR‑543, thus inhibiting CRC cell aggressive features. Collectively, the present results suggested that circ‑FOXO3 inhibited CRC metastasis and progression via elevated LATS1 expression by sponging miR‑543. Therefore, circ‑FOXO3 may be a promising target for CRC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.